On December 12, according to Gelonghui, Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently received the approval notice for the listing application of the Chemical Raw Materials for Nicorandil issued by the National Medical Products Administration. Nicorandil formulation is mainly used to treat angina.
赛隆药业(002898.SZ)：子公司获得化学原料药尼可地尔上市申请批准通知书
Sailong Pharmaceutical Group (002898.SZ): A subsidiary has received the approval notice for the listing application of the Chemical Raw Materials Active Pharmaceutical Ingredient Nicorandil.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.